- Home
- FINW vs CRVO Comparison
FINW vs CRVO Comparison
Compare FINW & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- CRVO
- Stock Information
- Founded
- FINW 1999
- CRVO 2001
- Country
- FINW United States
- CRVO United States
- Employees
- FINW N/A
- CRVO N/A
- Industry
- FINW Commercial Banks
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- CRVO Health Care
- Exchange
- FINW Nasdaq
- CRVO Nasdaq
- Market Cap
- FINW 212.8M
- CRVO 98.3M
- IPO Year
- FINW 2021
- CRVO N/A
- Fundamental
- Price
- FINW $15.33
- CRVO $2.13
- Analyst Decision
- FINW Buy
- CRVO Buy
- Analyst Count
- FINW 3
- CRVO 8
- Target Price
- FINW $18.67
- CRVO $38.75
- AVG Volume (30 Days)
- FINW 19.3K
- CRVO 476.7K
- Earning Date
- FINW 01-30-2025
- CRVO 11-12-2024
- Dividend Yield
- FINW N/A
- CRVO N/A
- EPS Growth
- FINW N/A
- CRVO N/A
- EPS
- FINW 1.06
- CRVO N/A
- Revenue
- FINW $69,509,000.00
- CRVO $10,066,550.00
- Revenue This Year
- FINW N/A
- CRVO $34.17
- Revenue Next Year
- FINW $10.13
- CRVO N/A
- P/E Ratio
- FINW $14.71
- CRVO N/A
- Revenue Growth
- FINW 4.87
- CRVO 116.29
- 52 Week Low
- FINW $8.72
- CRVO $1.80
- 52 Week High
- FINW $20.50
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- FINW 35.07
- CRVO 28.45
- Support Level
- FINW $15.51
- CRVO $1.99
- Resistance Level
- FINW $16.65
- CRVO $2.43
- Average True Range (ATR)
- FINW 0.71
- CRVO 0.17
- MACD
- FINW -0.07
- CRVO 0.31
- Stochastic Oscillator
- FINW 0.00
- CRVO 26.92
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.